Tests a phone app heart rehabilitation program for people with coronary heart disease
Tests a phone app rehab program in adults with coronary heart disease.
Plain-language title generated from the registry record
Registry title: Effectiveness of a Tele-cardiac Rehabilitation (Tele-CR) Program
Key facts
- Where
- Taoyuan, TaiwanSee the site
Where in Taiwan
- Chang Gung University of Science and TechnologyTaoyuan, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chang Gung University of Science and Technology
- Trial code
- NCT07110389
- Record updated
- 20 March 2026
- Original description
This study represents the second phase of a three-year research project aimed at evaluating both the short- and long-term effects of a six-month tele-cardiac rehabilitation (tele-CR) program in patients with coronary heart disease (CHD). The primary outcomes include quality of life, self-efficacy, self-management, medication adherence, and mental health (anxiety and depression). In addition, comprehensive metabolic parameters will be assessed, including body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1C), and lipid profile markers such as triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).Read full original descriptionShow less
Effectiveness of a Mobile Application-Based Tele-cardiac Rehabilitation (Tele-CR) Program for Patients With Coronary Heart Disease (CHD): A Randomized Clinical Trial
This study represents the second phase of a three-year research project aimed at evaluating both the short- and long-term effects of a six-month tele-cardiac rehabilitation (tele-CR) program in patients with coronary heart disease (CHD). The primary outcomes include quality of life, self-efficacy, self-management, medication adherence, and mental health (anxiety and depression). In addition, comprehensive metabolic parameters will be assessed, including body mass index (BMI), systolic and diastolic blood pressure (SBP and DBP), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1C), and lipid profile markers such as triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).
Inclusion: The main diagnosis at admission of CHD; Age ≥20 years; Owns an iOS or Android smartphone and can use it; Conscious, clear and can communicate; Agrees to participate in the research after explanation and is willing to use the App.
Exclusion: Planning to receive surgery (e.g., coronary artery bypass graft); Level IV on the New York Heart Association Functional Classification; Have a history of severe arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, complete atrioventricular block); Combined with other serious heart diseases (e.g., congenital heart disease, cardiomyopathy); Mental disorders, end-stage renal disease and other systemic diseases diagnosed by a physician; Severe infection, injury, surgery (e.g., coronary artery bypass graft) or cancer treatment has occurred in the past three months; Physical activities are affected by neurological, respiratory, skeletal, or peripheral vascular diseases; Restricted use of the App due to sensory or cognitive impairment; Left ventricular ejection fraction<40%; Already participated in other clinical trials.